No Anticholinergic Deprescription

No Anticholinergic Deprescription refers to the control intervention arm in a Phase 4 clinical trial (NCT04641598) led by Deepak K. Sarpal, M.D., which investigates the neural mechanisms of anticholinergic burden in mid- to late-life patients with schizophrenia or schizoaffective disorder. In this arm, participants continue their existing prescriptions of anticholinergic medications, specifically benztropine or trihexyphenidyl, without reduction or discontinuation. These medications are commonly used to manage extrapyramidal side effects associated with antipsychotic therapy. The study aims to evaluate how the maintenance of these drugs affects neurocognition, functional capacity, and quality of life compared to a structured deprescription protocol, thereby clarifying the impact of cumulative anticholinergic burden on the aging brain in the schizophrenia spectrum.

Other names

Maintenance of Anticholinergic TherapyAnticholinergic Maintenance